|
Mutagenic and carcinogenic potency determinations for NDMA support the cumulative dose assumption underpinning the less-than-lifetime Threshold of Toxicological Concern -Pub
|
|
0
|
156
|
April 21, 2026
|
|
Kinetic reaction rates for nitrosamine formation using secondary amines pKa
|
|
3
|
333
|
April 21, 2026
|
|
About the amlodipine nitrosamines
|
|
3
|
220
|
April 21, 2026
|
|
EMA's Revision of the Acceptance Limit for N-Nitroso-N-desmethyl-diphenhydramine
|
|
4
|
448
|
April 20, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
8
|
572
|
April 20, 2026
|
|
Potential for Nitrosamines in Medical Device Combination Products - Letter to Industry(FDA)
|
|
4
|
190
|
April 20, 2026
|
|
Etelcalcetide Nitroamide – is this possible?
|
|
0
|
72
|
April 18, 2026
|
|
Maximum Daily Dose (MDD) of Cream Formulation
|
|
1
|
191
|
April 17, 2026
|
|
🇺🇸 FDA Workshop - Nitrosamine-driven Reformulation and Bioequivelance
|
|
1
|
235
|
April 17, 2026
|
|
Toxycologist ... not for you!
|
|
2
|
238
|
April 17, 2026
|
|
Regarding the structural determination of N-nitrosyl abecacil
|
|
0
|
69
|
April 15, 2026
|
|
Stability Assessment of FDA Approved Varenicline Tartrate Products for Critical Quality Attributes – N-Nitroso Varenicline, Solid Form, and Dissolution-Pub
|
|
2
|
118
|
April 14, 2026
|
|
Testing of APIs for NDSRI
|
|
5
|
1315
|
April 12, 2026
|
|
FDA CRCG Workshop on Bioequivalence Innovations for Generic Oral Products
|
|
0
|
110
|
April 11, 2026
|
|
AMES Test Study Designs for Nitrosamine Mutagenicity Testing -Pub
|
|
13
|
1617
|
April 9, 2026
|
|
Excipient Selection Strategies to Mitigate Nitrosamine Risks
|
|
0
|
207
|
April 8, 2026
|
|
Would EDTA disodium form nitrosamines?
|
|
13
|
4518
|
April 8, 2026
|
|
N-Nitroso meglumine
|
|
26
|
2307
|
April 8, 2026
|
|
N-Nitrosamine Risk Management: From Toxicology to Targeted Analysis-Webinar
|
|
1
|
312
|
April 7, 2026
|
|
Society of Toxicology STO 2026 -Posters
|
|
1
|
116
|
April 7, 2026
|
|
Everthing you wanted to know about In vivo COMET assay -webinar
|
|
0
|
99
|
April 3, 2026
|
|
MDD for cream formulation
|
|
0
|
102
|
April 3, 2026
|
|
All are welcomed to participate in the Stakeholder Survey concerning a Potential USP Public Standard on Mutagenic Impurities
|
|
0
|
119
|
April 2, 2026
|
|
Question on the Method for Determining the Maximum Allowable Daily Usage of Terbinafine Ointment and Solution Formulations
|
|
2
|
167
|
April 2, 2026
|
|
🇸🇬 Singapore formalized Nitrosamine requirements for NDA and GDA Applications
|
|
0
|
132
|
April 1, 2026
|
|
FDA Announcement - Small Molecule Nitrosamines in Infusion Bags
|
|
17
|
2859
|
March 31, 2026
|
|
N-nitroso-Furosemide
|
|
2
|
530
|
March 31, 2026
|
|
Analysis method of cream
|
|
6
|
276
|
March 30, 2026
|
|
Determination of N-nitroso Caspofungin
|
|
1
|
119
|
March 27, 2026
|
|
Excipient Nitrosamine Risk Assessment Tool
|
|
1
|
522
|
March 26, 2026
|